By IDSE News Staff
The FDA approved eravacycline (Xerava, Tetraphase Pharmaceuticals) for the treatment of complicated intraabdominal infections (cIAIs).
Eravacycline is indicated for the treatment of cIAIs in patients aged 18 years and older.
The approval was based, in part, on results of the IGNITE (Investigating Gram-Negative Infections Treated with Eravacycline) phase 3 trials. In the first pivotal phase 3 trial in patients with cIAI, twice-daily IV eravacycline met the primary end